Get Help Sign In

N6-Methyl deoxyAdenosine (N6-Me-dA)

Product spotlight: Do you know about this competitive antagonist specific to P2Y1 receptors? N6-Methyl deoxyAdenosine (N6-Me-dA) modifications are useful in pharmacologic and research applications examining the effects of selective inhibition of P2Y1 receptors, which appear to play a role in blood clotting.

Quick facts:

Availability: DNA; can be ordered on an RNA oligo
Location: 5′ and internal
Scale: 100 nmol to large scale
Purification: Standard desalt or HPLC
IDT ordering symbol: /5N6Me-dA/ or /iN6Me-dA/

Figure 1. N6-Methyl deoxyAdenosine (N6-Me-dA).

N6-Methyl deoxyAdenosine (N6-Me-dA)

The N6-Methyl deoxyAdenosine (N6-Me-dA) modification consists of a methyl group at the nitrogen-6 position of a DNA base. It is a precursor of N6-methyl-2′-deoxyadenosine 3′, 5′-bisphosphate (N6MABP), a competitive antagonist specific to the P2Y1 receptors in the P2Y receptor family (see the below sidebar, P2Y receptors, to learn more). N6-Me-dA is useful in pharmacologic and research applications that examine the effects of selective inhibition of P2Y1 receptors, which appear to play a role in blood clotting.

Order N6-Me-dA as an off-catalog modification

N6-Me-dA is available from IDT as an “off-catalog” oligonucleotide modification on the 5′ base (/5N6Me-dA/) or an internal base (/iN6Me-dA/). Off-catalog modifications can be ordered through the website and are offered with yield and purity guarantees.

To order, enter your sequence online, placing the IDT ordering symbol in the desired location within your sequence. You can request N6-Me-dA oligonucleotides with standard desalt or HPLC purification.

Learn about other modifications to facilitate your research

See what other modifications are available from IDT. You can find a list of standard modifications we make to oligonucleotides on the Modifications page of our online catalog. And if you don’t find what you are looking for, just send us a request. We often synthesize special, non-catalog requests. Contact us at

P2Y receptors

The P2Y receptor family is comprised of at least 10 purinergic (membrane) G protein-coupled receptors found in most human tissues. Stimulated by A and U nucleotides and nucleosides, each receptor subtype mediates physiological functions through G-protein coupling to specific downstream signaling pathways [1]. Many of these receptors have clinical significance as drug targets, for example, for treatment of cystic fibrosis [2] and myocardial infarction [3]. The P2Y1 receptor appears to mediate platelet aggregation, when it binds ADP in these cells via activation of phospholipase C and mobilization of intracellular calcium ions, resulting in a change in platelet shape [4].


  1. Abbracchio MP, Burnstock G, et al. (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev, 58(3): 281–341. doi:10.1124/pr.58.3.3. PMC 3471216. PMID 16968944.
  2. Kellerman D, Evans R, et al. (2002) Inhaled P2Y2 receptor agonists as a treatment for patients with cystic fibrosis lung disease. Adv Drug Deliv Rev, 54(11):1463–74. doi:10.1016/S0169-409X(02)00154-0. PMID12458155.
  3. Amisten S, Melander O, et al. (2007) Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11. Eur Heart J, 28(1):13–8. doi:10.1093/eurheartj/ehl410. PMID 17135283.
  4. NCBI Entrez Gene. (updated August 9, 2015) P2RY1 purinergic receptor P2Y, G-protein coupled, 1 (Accessed August 10, 2015).

Published Aug 10, 2015
Revised/updated Dec 2, 2015